About Us
About Us

About EmbarkNeuro

EmbarkNeuro is a biotech company focused on bringing important new personalized treatments to patients with mental health disorders. Rates of major depression are rapidly rising, much of this attributable to the dramatic increase in stress brought on by the COVID-19 pandemic. We are focusing on identifying depressed individuals with a potential biomarker linked to the stress response system (elevated cortisol) and developing ANC-501 as a new treatment specifically for these patients. The time is right to think anew about how best to match patients to new treatments focusing on the underlying driver of symptoms.

1 in 3 patients
still do not have an adequate response after 4 lines of therapy.
ANC-501 Clinical Trial
Learn More >

1  Terlizzi, E. P., & Schiller, J. S. (2021). Estimates of mental health symptomatology, by month of interview: United States, 2019. National Center for Health Statistics. Available at www.cdc.gov/nchs/data/nhis/mental-health-monthly-508.pdf.

2  National Center for Health Statistics Household Pulse Survey data on anxiety and depression collected between April 23, 2020, and Oct. 11, 2021. Available at www.cdc.gov/nchs/covid19/pulse/mental-health.htm.

3  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
 A John Rush 1, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz, Patrick J McGrath, Jerrold F Rosenbaum, Harold A Sackeim, David J Kupfer, James Luther, Maurizio Fava